US Stock Movement: Twist Bioscience surged on October 9 as price target was raised and trading was launched

Twist Bioscience October 9 Surge Interpretation

Keywords: Target Price Increase, Trading Launch

1. On October 9, Barclays maintained a "Buy" rating on Twist Bioscience and raised its target price from $112 to $215. The rating and target price adjustment constituted a direct company-level catalyst for the day.

2. On October 8, Trade.xyz announced the launch of TWST trading and support for up to 10x leverage. Twist Bioscience mainly focuses on gene synthesis and related biotechnology tools, and the expansion of trading channels has improved the stock’s accessibility.

3. On August 3, the company disclosed that for the fiscal quarter ending June 30, revenue increased by 23% year-on-year to $118.4 million. DNA synthesis and protein solutions revenue grew by 39%, NGS application revenue grew by 12%, and gene shipments increased by 56% year-on-year to approximately 369,000. The main business continues to grow rapidly.

(Disclaimer: This content is generated by AI summarizing publicly available information and is for reference only. It does not constitute investment advice.)